PlumX Metrics
Embed PlumX Metrics

Chronic myeloid leukemia

Onkologe, ISSN: 1433-0415, Vol: 24, Issue: 5, Page: 427-442
2018
  • 3
    Citations
  • 0
    Usage
  • 90
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

The advent of tyrosine kinase inhibitors (TKI) imatinib has considerably improved prognosis of patients with chronic myeloid leukemia (CML). In comparison to imatinib, first-line use of second-generation inhibitors nilotinib, dasatinib, and bosutinib has led to faster and deeper molecular remissions accompanied by a novel adverse event profile. Long-lasting treatment-free remission in an important minority of patients prompted the hope for curability of CML. An essential part of the management of CML patients is consequent cytogenetic and molecular follow-up with standardized methods to regularly assess the remission status. The use of interferon-α in parallel with or after TKI therapy is associated with the induction of an immune response against the leukemic clone with further improvement of the remission rate. A novel allosteric kinase inhibitor (asciminib) could further improve treatment of CML patients in the near future.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know